Cargando…

Hepatitis C virus infection in chronic kidney disease: paradigm shift in management

Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is associated with increased liver-related morbidity and mortality rates, accelerated progression to end-stage renal disease, and risk of cardiovascular events. CKD patients with HCV infection require antiviral therapy. Pegylated inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, So Mi, Song, Il Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030406/
https://www.ncbi.nlm.nih.gov/pubmed/29961309
http://dx.doi.org/10.3904/kjim.2018.202
_version_ 1783337146135871488
author Kim, So Mi
Song, Il Han
author_facet Kim, So Mi
Song, Il Han
author_sort Kim, So Mi
collection PubMed
description Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is associated with increased liver-related morbidity and mortality rates, accelerated progression to end-stage renal disease, and risk of cardiovascular events. CKD patients with HCV infection require antiviral therapy. Pegylated interferon (peg-IFN) plus ribavirin was the standard of care for HCV-infected CKD patients before the introduction of first-generation direct-acting antiviral (DAA) oral anti-HCV agents. Peg-IFN-based treatment has a low virologic response rate and poor compliance, resulting in a high dropout rate. Recently, several clinical trials of all-DAA combination regimens have reported excellent antiviral efficacy and few adverse drug reactions in HCV-infected patients with CKD. These positive results have revolutionized the treatment of chronic HCV infection in this population. In this review, we address the impact of chronic HCV infection in CKD patients, and discuss their management using next-generation DAAs.
format Online
Article
Text
id pubmed-6030406
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-60304062018-07-06 Hepatitis C virus infection in chronic kidney disease: paradigm shift in management Kim, So Mi Song, Il Han Korean J Intern Med Review Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is associated with increased liver-related morbidity and mortality rates, accelerated progression to end-stage renal disease, and risk of cardiovascular events. CKD patients with HCV infection require antiviral therapy. Pegylated interferon (peg-IFN) plus ribavirin was the standard of care for HCV-infected CKD patients before the introduction of first-generation direct-acting antiviral (DAA) oral anti-HCV agents. Peg-IFN-based treatment has a low virologic response rate and poor compliance, resulting in a high dropout rate. Recently, several clinical trials of all-DAA combination regimens have reported excellent antiviral efficacy and few adverse drug reactions in HCV-infected patients with CKD. These positive results have revolutionized the treatment of chronic HCV infection in this population. In this review, we address the impact of chronic HCV infection in CKD patients, and discuss their management using next-generation DAAs. The Korean Association of Internal Medicine 2018-07 2018-06-28 /pmc/articles/PMC6030406/ /pubmed/29961309 http://dx.doi.org/10.3904/kjim.2018.202 Text en Copyright © 2018 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Kim, So Mi
Song, Il Han
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
title Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
title_full Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
title_fullStr Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
title_full_unstemmed Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
title_short Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
title_sort hepatitis c virus infection in chronic kidney disease: paradigm shift in management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030406/
https://www.ncbi.nlm.nih.gov/pubmed/29961309
http://dx.doi.org/10.3904/kjim.2018.202
work_keys_str_mv AT kimsomi hepatitiscvirusinfectioninchronickidneydiseaseparadigmshiftinmanagement
AT songilhan hepatitiscvirusinfectioninchronickidneydiseaseparadigmshiftinmanagement